Bonus BioGroup Gains From Start of Clinical Trials of Stem Cell Derived Bone … – Jewish Business News
|
Bonus BioGroup Gains From Start of Clinical Trials of Stem Cell Derived Bone …
Jewish Business News Bonus Biogroup Ltd. (TASE: BONS), which has developed a method for producing bone grafts from stem cells, has begun a clinical trial of jawbone grafts. The trial’s interim results are due in four months. Bonus Biogroup’s share price rose 10.4% in … |
